GanLum delivered a 97.4% cure rate for Malaria in landmark phase III trial
Novartis has announced compelling Phase III results for GanLum (ganaplacide/lumefantrine, KLU156), a next-generation antimalarial developed with Medicines for Malaria Venture (MMV). The combination therapy achieved a 97.4% PCR-corrected cure rate in the KALUMA study marking a major advancement in malaria treatment amid rising drug resistance across Africa.










